Post
Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial
Sanofi has announced that its anti-CD40L antibody frexalimab demonstrated significantly reduced disease activity in a Phase II trial of patients …
AstraZeneca and MSD’s Lynparza combo bags FDA approval for prostate cancer
The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD’s Lynparza (olaparib), with standard therapies …
Pneumagen raises £8 million for further study of intranasal antiviral
Pneumagen has raised £8m ($10 million) for the further development of its intranasal antiviral drug neumifil in Phase II studies …
InDex Pharmaceuticals signs licence deal with Viatris for cobitolimod
InDex Pharmaceuticals has entered a licence deal with Viatris Pharmaceutical Japan for the development and commercialisation of cobitolimod in Japan …
Algernon announces acceptance of Repirinast patent application in Japan
Algernon Pharmaceuticals’ patent application for NP-251 (Repirinast) has been accepted by the Japanese Patent Office (JPO) for the treatment of …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Negative FDA AdCom vote for Intercept’s obeticholic acid in NASH
On 19 May, the FDA’s Gastrointestinal Drugs Advisory Committee (GDAC), by a vote of 12 to two, with two abstentions, …
UK’s NICE recommends Pfizer’s rimegepant to treat migraine
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Pfizer’s …
USPTO grants Notice of Allowance for Tenax Therapeutics’ oral levosimendan
The US Patent and Trademark Office (USPTO) has granted a Notice of Allowance for Tenax Therapeutics’ patent application covering its …
New UK intracellular drug delivery centre to support RNA development
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and …
FDA approves Analog and Dipharma’s ANDA for nitisinone capsules
The US Food and Drug Administration (FDA) has granted clearance to Analog Pharma and Dipharma’s abbreviated new drug application (ANDA) …
(Cilnidipine + tadalafil) by AISA Pharma for Raynauds Disease: Likelihood of Approval
(Cilnidipine + tadalafil) is under clinical development by AISA Pharma and currently in Phase II for Raynauds Disease. According to …
RO-7446603 by Genentech USA for Diabetic Macular Edema: Likelihood of Approval
RO-7446603 is under clinical development by Genentech USA and currently in Phase I for Diabetic Macular Edema. According to GlobalData, …
TQB-3454 by Chia Tai Tianqing Pharmaceutical Group for Solid Tumor: Likelihood of Approval
TQB-3454 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor. According …
Decoy-20 by Indaptus Therapeutics for Colorectal Cancer: Likelihood of Approval
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase …
Sintilimab by Innovent Biologics for Metastatic Melanoma: Likelihood of Approval
Sintilimab is under clinical development by Innovent Biologics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase …